Arrowhead Pharmaceuticals (ARWR) Common Equity (2010 - 2026)

Arrowhead Pharmaceuticals' Common Equity history runs 17 years deep, the most recent figure standing at $614.0 million for Q1 2026.

• Quarterly Common Equity fell 10.27% year-over-year to $614.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $614.0 million (down 10.27% YoY) and the FY2025 annual result came in at $466.1 million, up 143.93% from the prior year.
• Common Equity was $614.0 million for Q1 2026 at Arrowhead Pharmaceuticals, up from $562.7 million in the prior quarter.
• Across five years, Common Equity topped out at $684.2 million in Q1 2025 and bottomed at $56.1 million in Q4 2024.
• A 5-year average of $410.6 million and a median of $452.3 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity slumped 67.72% — and 2025, when it soared 903.47%.
• Arrowhead Pharmaceuticals' Common Equity stood at $396.4 million in 2022, then tumbled by 56.17% to $173.7 million in 2023, then slumped by 67.72% to $56.1 million in 2024, then surged by 903.47% to $562.7 million in 2025, then grew by 9.11% to $614.0 million in 2026.
• Business Quant data shows ARWR's Common Equity at $614.0 million in Q1 2026, $562.7 million in Q4 2025, and $466.1 million in Q3 2025.